Comparative Pharmacology
Head-to-head clinical analysis: INCIVEK versus LIVTENCITY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INCIVEK versus LIVTENCITY.
INCIVEK vs LIVTENCITY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibitor of the HCV NS3/4A serine protease, preventing cleavage of the HCV polyprotein, thereby inhibiting viral replication.
LIVTENCITY (maribavir) is an inhibitor of the human cytomegalovirus (CMV) UL97 protein kinase, which is essential for viral DNA replication, encapsidation, and egress of mature virions from the infected cell. By blocking UL97 kinase activity, maribavir inhibits viral replication.
Incivek (telaprevir) is administered orally at a dose of 750 mg (two 375 mg tablets) three times daily (every 7-9 hours) with food (not low-fat).
200 mg orally once daily with food.
None Documented
None Documented
Terminal elimination half-life ranges from 4 to 13 hours (mean ~7 hours) in healthy volunteers; prolonged to 10-20 hours in HCV-infected patients.
Terminal elimination half-life is approximately 20 hours, supporting once-daily dosing for sustained antiviral activity.
Approximately 91% of the radiolabeled dose is recovered in feces (79% as unchanged drug) and 9% in urine (1% as unchanged drug).
Primarily hepatobiliary excretion; unchanged drug and metabolites eliminated in feces (86%) and urine (14%).
Category C
Category C
Antiviral
Antiviral